Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carlumab

Next Previous
Drug Profile

Carlumab

Alternative Names: Anti-CCL2 monoclonal antibody Centocor; Anti-chemokine ligand 2 monoclonal antibody Centocor; Anti-MCP-1 monoclonal antibody Centocor; Anti-monocyte chemoattractant protein 1-monoclonal antibody Centocor; Anti-monocyte chemotactic protein 1 monoclonal antibody Centocor; CNTO-888; Fully human antibody therapeutic for immunology/oncology - Janssen Biotech/MorphoSys

Latest Information Update: 26 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer Janssen Biotech
  • Class Antifibrotics; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Chemokine CCL2 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Idiopathic pulmonary fibrosis; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 20 May 2013 Final efficacy data from a phase II trial in Idiopathic pulmonary fibrosis released by Janssen
  • 09 May 2012 Carlumab is still in phase II development for Idiopathic pulmonary fibrosis
  • 31 Mar 2012 Discontinued - Phase-I for Solid tumours in Spain (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top